Condition: Chinese Patients with Chronic Myeloid Leukemia (CML)
Journal: Journal of hematology & oncology
Treatment Used: Olverembatinib
Number of Patients: 165
Published: August 18, 2022
Summary: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial.
Condition: Philadelphia Chromosome-Positive Chronic Myeloid Leukemia
Journal: International journal of hematology
Treatment Used: Nilotinib
Number of Patients: 129
Published: February 25, 2022
Summary: NOVEL-1st: an observational study to assess the safety and efficacy of nilotinib in newly diagnosed patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase in Taiwan.